Zai Lab (ZLAB) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue was $108.2M, down 7% YoY and up 1.8% QoQ; net loss widened to $46.1M from $36.0M.

• Three pivotal zoci studies are targeted by year-end 2026, with two registrational readouts and a potential first U.S. BLA submission in 2027.

• Commercial trends were mixed, while management targeted a return to meaningful revenue growth in 2027 as patient access expands.

Financial highlights

• Q3 total revenue was $108.2M versus $116.1M YoY; net product revenue was $107.6M versus $115.4M, down 7% reported and up 29% at CER.

• Q3 GAAP operating loss was $63.0M versus $48.8M; adjusted operating loss was $47.6M. Net loss was $46.1M versus $36.0M YoY.

• Q3 R&D expense was $49.8M versus $47.9M YoY; SG&A was $70.1M in both periods.

• Nine-month revenue was $314.1M versus $332.6M; net loss was $148.0M versus $125.1M YoY.

Outlook and guidance

• Three registrational zoci studies across SCLC and neuroendocrine carcinomas are targeted by year-end 2026; two registrational readouts and a potential U.S. BLA submission are anticipated in 2027.

• A global Phase 3 zoci plus PD-L1 study in first-line ES-SCLC is planned by year-end 2026; DLLEVATE interim analysis is expected in H2 2027.

• Zoci 2L+ epNEC topline data are expected in H1 2027 and could support a U.S. accelerated approval submission; a U.S. launch could follow as early as 2028.

• ZL-1503 atopic dermatitis patient data and ZL-6201 dose-escalation topline results are expected in H1 2027; ZL-1503 Phase 2 initiation is planned for 2027.

• Meaningful revenue growth is targeted for 2027, supported by expanded patient access, priority-brand demand and potential NRDL-driven volume growth.